Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

RETRACTED ARTICLE: CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus

Oncogene volume 24, pages 5543–5551 (2005)Cite this article

This article was retracted on 17 October 2022

This article has been updated

Abstract

Control of cell proliferation by Polycomb group proteins (PcG) is an important facet of cellular homeostasis and its disruption can promote tumorigenesis. We recently described CBX7 as a novel PcG protein controlling the growth of normal cells. In an attempt to identify a putative role of CBX7 in tumorigenesis, we analysed CBX7 expression in a panel of cancer cell lines and primary tissues. CBX7 was highly expressed in three different prostate cancer cell lines and present at elevated levels in normal prostate. Ablation of CBX7 expression using short hairpin RNAs (shRNA) resulted in upregulation of p16Ink4a and p14Arf in both LNCaP and PC-3 prostate cell lines. CBX7 knockdown caused an impairment of cell growth that was dependent on the status of the p14Arf/p53 and p16Ink4a/Rb pathways in both normal and cancer prostate cells. CBX7 overexpression in LNCaP cells resulted in a slight growth advantage in both androgen-dependent and -independent conditions. Moreover, CBX7 expression cooperated with c-Myc in rendering LNCaP cells insensitive to growth arrest by androgen receptor inhibition. Together, these data suggest that CBX7 represses p16Ink4a and p14Arf expression in normal and tumor-derived prostate cells, affecting their growth depending on the status of the p16Ink4a/Rb and the p14Arf/p53 pathways.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

Change history

References

  • Abate-Shen C and Shen MM . (2000). Genes Dev., 14, 2410–2434.

  • Baylin SB and Herman JG . (2000). Trends Genet., 16, 168–174.

  • Bea S, Tort F, Pinyol M, Puig X, Hernandez L, Hernandez S, Fernandez PL, van Lohuizen M, Colomer D and Campo E . (2001). Cancer Res., 61, 2409–2412.

  • Bernard D, Pourtier-Manzanedo A, Gil J and Beach DH . (2003). J. Clin. Invest., 112, 1724–1731.

  • Bracken AP, Pasini D, Capra M, Prosperini E, Colli E and Helin K . (2003). EMBO J., 22, 5323–5335.

  • Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS and Zhang Y . (2002). Science, 298, 1039–1043.

  • Carroll AG, Voeller HJ, Sugars L and Gelmann EP . (1993). Prostate, 23, 123–134.

  • Chi SG, deVere White RW, Muenzer JT and Gumerlock PH . (1997). Clin. Cancer Res., 3, 1889–1897.

  • Drayton S, Rowe J, Jones R, Vatcheva R, Cuthbert-Heavens D, Marshall J, Fried M and Peters G . (2003). Cancer Cell, 4, 301–310.

  • Feldman BJ and Feldman D . (2001). Nat. Rev. Cancer, 1, 34–45.

  • Francis NJ and Kingston RE . (2001). Nat. Rev. Mol. Cell. Biol., 2, 409–421.

  • Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N and Stratton MR . (2004). Nat. Rev. Cancer, 4, 177–183.

  • Gil J, Bernard D, Martinez D and Beach D . (2004). Nat. Cell Biol., 6, 67–72.

  • Hanahan D and Weinberg RA . (2000). Cell, 100, 57–70.

  • Hudson DL, O'Hare M, Watt FM and Masters JR . (2000). Lab. Invest., 80, 1243–1250.

  • Jacobs JJL and van Lohuizen M . (2002). Biochim Biophys Acta (BBA) Rev. Cancer, 1602, 151–161.

  • Jones PA . (2002). Oncogene, 21, 5358–5360.

  • Kanno M, Hasegawa M, Ishida A, Isono K and Taniguchi M . (1995). EMBO J., 14, 5672–5678.

  • Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A and Green DR . (1998). Mol. Cell, 1, 543–551.

  • Kirmizis A, Bartley SM and Farnham PJ . (2003). Mol. Cancer Ther., 2, 113–121.

  • Kirmizis A, Bartley SM, Kuzmichev A, Margueron R, Reinberg D, Green R and Farnham PJ . (2004). Genes Dev., 18, 1592–1605.

  • Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RGAB, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA and Chinnaiyan AM . (2003). Proc. Natl. Acad. Sci. USA, 100, 11606–11611.

  • Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P and Reinberg D . (2002). Genes Dev., 16, 2893–2905.

  • Lessard J and Sauvageau G . (2003). Nature, 423, 255–260.

  • Lu S, Tsai SY and Tsai MJ . (1997). Cancer Res., 57, 4511–4516.

  • Lund AH and van Lohuizen M . (2004). Curr. Opin. Cell Biol., 16, 239–246.

  • Muyrers-Chen I and Paro R . (2001). Biochim. Biophys. Acta (BBA) Rev. Cancer, 1552, 15–26.

  • Nelson WG, De Marzo AM and Isaacs WB . (2003). N. Engl. J. Med., 349, 366–381.

  • Nupponen NN, Kakkola L, Koivisto P and Visakorpi T . (1998). Am. J. Pathol., 153, 141–148.

  • Otte AP and Kwaks TH . (2003). Curr. Opin. Genet. Dev., 13, 448–454.

  • Pasini D, Bracken AP and Helin K . (2004). Cell Cycle, 3, 396–400.

  • Porkka KP and Visakorpi T . (2004). Eur. Urol., 45, 683–691.

  • Raaphorst FM, van Kemenade FJ, Blokzijl T, Fieret E, Hamer KM, Satijn DP, Otte AP and Meijer CJ . (2000). Am. J. Pathol., 157, 709–715.

  • Satijn D, Olson D, van der Vlag J, Hamer K, Lambrechts C, Masselink H, Gunster M, Sewalt R, van Driel R and Otte A . (1997). Mol. Cell. Biol., 17, 6076–6086.

  • Tokimasa S, Ohta H, Sawada A, Matsuda Y, Kim JY, Nishiguchi S, Hara J and Takihara Y . (2001). Exp. Hematol., 29, 93–103.

  • van Kemenade FJ, Raaphorst FM, Blokzijl T, Fieret E, Hamer KM, Satijn DP, Otte AP and Meijer CJ . (2001). Blood, 97, 3896–3901.

  • Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RGAB, Otte AP, Rubin MA and Chinnaiyan AM . (2002). Nature, 419, 624–629.

  • Visakorpi T . (2003). Urology, 62, 3–10.

  • Visakorpi T, Kallioniemi AH, Syvanen AC, Hyytinen ER, Karhu R, Tammela T, Isola JJ and Kallioniemi OP . (1995). Cancer Res., 55, 342–347.

  • Visser HP, Gunster MJ, Kluin-Nelemans HC, Manders EM, Raaphorst FM, Meijer CJ, Willemze R and Otte AP . (2001). Br. J. Haematol., 112, 950–958.

  • Wang J, Xie LY, Allan S, Beach D and Hannon GJ . (1998). Genes Dev., 12, 1769–1774.

  • Wang L, Brown JL, Cao R, Zhang Y, Kassis JA and Jones RS . (2004). Mol. Cell, 14, 637–646.

  • Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ and Roussel MF . (1998). Genes Dev., 12, 2424–2433.

Download references

Acknowledgements

We thank members of D Beach laboratory for helpful suggestions and discussion. Cancer Research UK supported this investigation. Part of this work was supported by the Spanish MCyT (project BIO2001-0069) to AC. JG and DB are recipients of a long-term fellowship from HFSP and a Marie Curie Intra-European fellowship, respectively.

Author information

Authors and Affiliations

  1. Laboratory of Molecular Virology, Faculty of Medicine, Free University of Brussels, Brussels, Belgium

    David Bernard

  2. Experimental Therapeutics Program, Centro Nacional de Investigaciones Oncológicas, Melchor Fernández Almagro 3, Madrid, 28029, Spain

    Juan F Martinez-Leal & Amancio Carnero

  3. Prostate Stem Cell Laboratory, Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK

    Sian Rizzo & David Hudson

  4. Wolfson Institute for Biomedical Research, University College London, Gower Street, London, WC1E 6BT, UK

    Dolores Martinez

  5. Cancer Genetics, Institute of Medical Technology, University of Tampere and Tampere University Hospital, FIN-33014 University of Tampere, Tampere, Finland

    Tapio Visakorpi

  6. Molecular Oncology Laboratory, Cancer Research UK, London Research Institute, 44 Lincoln's Inn Fields, London, WC2A 3PX, UK

    Gordon Peters & Jesus Gil

  7. Center for Cutaneous Biology, Institute for Cell and Molecular Sciences, 2 Newark St, Whitechapel, London, E1 2AT, UK

    David Beach

Authors
  1. David Bernard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Juan F Martinez-Leal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sian Rizzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dolores Martinez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David Hudson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tapio Visakorpi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gordon Peters
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Amancio Carnero
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. David Beach
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jesus Gil
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jesus Gil.

Additional information

Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)

Supplementary information

About this article

Cite this article

Bernard, D., Martinez-Leal, J., Rizzo, S. et al. RETRACTED ARTICLE: CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus. Oncogene 24, 5543–5551 (2005). https://doi.org/10.1038/sj.onc.1208735

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208735

Keywords

This article is cited by

Search

Advanced search

Quick links